Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02535221 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 29, 2021 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Jan 2025 to Jun 30, 2026
    • Study completion date: Jun 2025 to Dec 31, 2026
    v5
  2. Re-verified, no change to tracked fieldsv4
  3. Primary completion date: Jun 2019 to Jan 2025
    • Study completion date: Dec 2019 to Jun 2025
    • Start date: Jul 1, 2015 to Jul 29, 2015
    v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date: Sep 2015 to Jul 1, 2015
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Peking University
118 trials monitored
See 4 trials at risk
Breast Cancer
5,418 trials monitored
See 296 trials at risk
This study proposes to prove that the efficacy of adjuvant endocrine therapy for the premenopausal HR positive breast cancer patients is non-inferiority to adjuvant chemotherapy assessed by ultrasound response rate.
Trial Details
NCT Number NCT02535221
Lead Sponsor Peking University
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 234 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov